ASCO: Adding Olaparib Slows High - Risk Early Breast Cancer

Higher rates of invasive disease - free survival seen in adjuvant setting for HER2 - negative early - stage disease with germline BRCA1 or BRCA2 mutations
Source: The Doctors Lounge - Oncology - Category: Cancer & Oncology Tags: Gynecology, Oncology, Pharmacy, Conference News, Source Type: news